最新消息
News
漢康-KY第二屆技術研發日揭示全球成長策略與多元產品線布局 HanchorBio Outlines Global Growth Strategy and Multi-Asset Pipeline at Second Annual R&D Day
HanchorBio hosted its second R&D Day. The Company presented its evolution from a single-asset clinical validation model into a multi-asset, macrophage-directed immunotherapy platform with global commercial potential.
9 月 23, 2026
Read more
漢康生技五項臨床研究入選 CSCO 2026 HanchorBio to Present Five Clinical Abstracts at CSCO 2026
HanchorBio announced that five company-sponsored clinical abstracts have been accepted for presentation at the 29th Annual Meeting of the Chinese Society of Clinical Oncology (CSCO 2026).
9 月 18, 2026
Read more
漢康生技將於 BioCon China Expo 2026 分享巨噬細胞增強平台與免疫治療布局 HanchorBio Advances Its Myeloid Enhancer Platform at BioCon China Expo 2026
HanchorBio announced that Founder and Chairman Dr. Scott Liu will present at BioCon China Expo 2026 on September 15.
9 月 14, 2026
Read more
漢康-KY受邀出席統一證券秋季投資論壇 分享臨床開發、產品布局與全球化策略 HanchorBio Highlights Clinical, Pipeline, and Global Growth Strategy
HanchorBio highlighted its clinical development, pipeline expansion, and global growth strategy following a presentation at the “2026 Q3 Global Outlook Autumn Investment Forum” hosted by President Securities at Grand Hyatt Taipei.
9 月 08, 2026
Read more
漢康生技 HCB101 與 HCB301 雙獲 KSMO/FACO 2026 肯定 HanchorBio Earns Dual KSMO/FACO 2026 Recognition for HCB101 and HCB301
HanchorBio announced clinical results from HCB101 and HCB301 presented at KSMO 2026—the 19th Annual Meeting of the Korean Society of Medical Oncology and 2026 International Conference—held in conjunction with the 14th International Conference of the Federation of Asian Clinical Oncology (FACO), in Seoul, South Korea.
9 月 07, 2026
Read more
漢康生技將於 2026 Jefferies亞太醫療健康大會分享產品線策略 HanchorBio to Present Pipeline Strategy at 2026 Jefferies APAC Healthcare Conference
HanchorBio announced that executive management will participate in the 2026 Jefferies APAC Healthcare Conference, taking place September 20–21, 2026, at Hilton Shanghai Zhangjiang Science Park in Shanghai.
9 月 01, 2026
Read more
漢康-KY受邀於臨床試驗論壇分享胃癌免疫治療全球開發策略 HCB101邁向第一期臨床後新階段 HanchorBio Outlines Global Strategy for Gastric Cancer Immunotherapy as HCB101 Advances Beyond Phase 1
HanchorBio announced that Alvin Luk, PhD, MBA, CCRA, President and Chief Medical Officer (Group) and CEO (USA) of HanchorBio, presented the Company’s vision for the next phase of gastric cancer immunotherapy at the Early Phase Clinical Trials: Innovation and Precision Medicine Forum in Taichung, Taiwan.
8 月 24, 2026
Read more
漢康-KY受邀於產業論壇分享髓系細胞導向治療策略 HCB101臨床進展支持FBDB™平台拓展至腫瘤以外疾病領域 HanchorBio Advances Myeloid-Directed Therapeutics Strategy Beyond Oncology with HCB101 Clinical Progress and FBDB™ Platform Expansion
HanchorBio shared its latest clinical and research progress in myeloid-directed therapeutics at the 2026 Autumn Industry Trends and Corporate Forum hosted by Hua Nan Securities. The Company presented its development strategy centered on the proprietary FBDB™ multifunctional biologics platform and myeloid enhancer approach, highlighting clinical progress of HCB101 in solid tumors and the expansion of macrophage-directed biology into HCB206 for immune-mediated diseases.
8 月 21, 2026
Read more
漢康生技 HCB301 獲選 KSMO 2026 口頭報告 HCB101 胃癌研究榮獲最佳海報發表獎 HanchorBio Announces HCB301 Oral Presentation and HCB101 Best Poster Selection at KSMO 2026
HanchorBio announced that three abstracts featuring its clinical-stage programs HCB101 and HCB301 have been accepted for presentation at KSMO 2026—the 19th Annual Meeting of the Korean Society of Medical Oncology and 2026 International Conference—held in conjunction with the 14th International Conference of the Federation of Asian Clinical Oncology (FACO), taking place September 2–4, 2026, in Seoul, Korea.
8 月 19, 2026
Read more
從巨噬細胞生物學到臨床開發： 漢康生技推進胃癌免疫治療的未來 From Macrophage Biology to Clinical Development: HanchorBio Advances the Future of Gastric Cancer Immunotherapy
HanchorBio announced insights from the “Taiwan Gastric Cancer Experts Forum on Clinical Challenges and Emerging Immunotherapy”, held August 8–9 in Taichung, Taiwan.
8 月 10, 2026
Read more